Nippon Chemiphar Co Ltd

Nippon Chemiphar maintains a relatively strong liquidity position, with cash and equivalents of ¥9.2 billion, but its long-term debt of ¥16.98 billion exceeds its cash reserves, resulting in a negative net cash position. The company's debt-to-equity ratio of 0.92 suggests a moderate level of leverage, while its current ratio of 2.31 indicates sufficient short-term liquidity to cover its obligations. However, the negative operating income of ¥458 million and net loss of ¥285 million highlight a deteriorating profitability profile.

The company's return on equity of -1.54% and return on assets of -0.58% are significantly below the industry median for pharmaceutical firms, which typically report positive returns in the 5-10% range. Gross profit of ¥1.89 billion represents 24.6% of revenue, which is in line with the industry average, but the failure to convert this into operating profit suggests inefficiencies in cost management or pricing power.

Nippon Chemiphar's revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond Japan. This lack of diversification increases exposure to domestic regulatory, economic, and competitive pressures. The company's capital expenditures of ¥2.64 billion in the latest period suggest ongoing investment in R&D or production capabilities, but the absence of segment-specific breakdowns limits visibility into the drivers of these expenditures.

The company's revenue of ¥7.68 billion in the latest period is below the analyst estimate of ¥32.57 billion, indicating a significant underperformance relative to expectations. The negative operating and net income figures suggest a challenging operating environment, potentially driven by pricing pressures, R&D write-downs, or competitive dynamics in its core therapeutic areas. The outlook for the next fiscal year remains uncertain, with no clear indication of a turnaround in profitability or revenue growth.

The risk assessment highlights a medium liquidity risk, primarily due to the negative net cash position after accounting for long-term debt. While dilution risk is currently rated as low, the company's negative net income and operating cash flow of only ¥297 million raise concerns about its ability to fund operations without external financing. The absence of a clear path to profitability increases the likelihood of future capital-raising activities, which could dilute existing shareholders.

Recent filings and transcripts do not provide detailed insights into the company's strategic direction or operational performance. The lack of recent public commentary or investor updates suggests limited transparency into the company's near-term plans or challenges.

Net income surged 262.4% year-over-year to JPY 294 million in fiscal 2025, signaling a strong profitability recovery.

Operating income jumped 155.3% to JPY 264 million in fiscal 2025, demonstrating significant improvement in core operational efficiency.

Revenue grew 5.9% year-over-year to JPY 32.57 billion in fiscal 2025, indicating modest but positive top-line expansion.

Free cash flow improved by 76.0% year-over-year in fiscal 2025, showing a notable reduction in cash burn rates.

Dilution risk is assessed as low, suggesting current capital structure stability despite recent financial volatility and losses.

Operating margin of -5.96% remains significantly below the pharmaceutical cohort median of 5.6%, indicating persistent structural inefficiencies.

Debt-to-equity ratio of 0.92 places the company in the bottom quartile, reflecting high leverage compared to peers.

Credit risk is flagged as high, raising concerns about the company's ability to meet its financial obligations reliably.

Long-term debt increased to JPY 18.06 billion in fiscal 2025, exacerbating financial burden amidst negative free cash flow.

Revenue ¥8.32B, −4,1% YoY; Operating income +269,6% YoY.

• ▍Revenue ¥8.32B, −4,1% YoY
• ▍Operating income +269,6% YoY
• ▍Net income +53,1% YoY
• ▍Net margin 1.5%

Revenue ¥7.68B, +0,7% YoY; Operating income −250,7% YoY.

• ▍Revenue ¥7.68B, +0,7% YoY
• ▍Operating income −250,7% YoY
• ▍Net income +62,8% YoY
• ▍Net margin -0.8%

Revenue ¥8.25B, +3,1% YoY; Operating income +7 633,3% YoY.

• ▍Revenue ¥8.25B, +3,1% YoY
• ▍Operating income +7 633,3% YoY
• ▍Net income +78,7% YoY
• ▍Net margin 2.8%

Revenue ¥8.26B, +7,6% YoY; Operating income +136,0% YoY.

• ▍Revenue ¥8.26B, +7,6% YoY
• ▍Operating income +136,0% YoY
• ▍Net income +190,5% YoY
• ▍Net margin 3.1%

Revenue ¥8.68B; Operating income ¥23.0M.

• ▍Revenue ¥8.68B
• ▍Operating income ¥23.0M
• ▍Net margin 0.9%

Revenue ¥7.63B; Operating income ¥73.0M.

• ▍Revenue ¥7.63B
• ▍Operating income ¥73.0M
• ▍Net margin -2.3%

Revenue ¥8.00B; Operating income ¥3.0M.

• ▍Revenue ¥8.00B
• ▍Operating income ¥3.0M
• ▍Net margin 1.6%

Revenue ¥7.68B; Operating income -¥458.0M.

• ▍Revenue ¥7.68B
• ▍Operating income -¥458.0M
• ▍Net margin -3.7%

Revenue ¥32.57B, +5,9% YoY; Operating income +155,3% YoY.

• ▍Revenue ¥32.57B, +5,9% YoY
• ▍Operating income +155,3% YoY
• ▍Net income +262,4% YoY
• ▍Free cash flow +76,0% YoY
• ▍Net margin 0.9%

Revenue ¥30.75B, −2,6% YoY; Operating income −98,8% YoY.

• ▍Revenue ¥30.75B, −2,6% YoY
• ▍Operating income −98,8% YoY
• ▍Net income −153,4% YoY
• ▍Free cash flow −339,9% YoY
• ▍Net margin -0.6%

Revenue ¥31.56B, −2,9% YoY; Operating income −137,6% YoY.

• ▍Revenue ¥31.56B, −2,9% YoY
• ▍Operating income −137,6% YoY
• ▍Net income −51,6% YoY
• ▍Free cash flow −53,4% YoY
• ▍Net margin 1.1%

Revenue ¥32.51B, +3,1% YoY; Operating income +56,4% YoY.

• ▍Revenue ¥32.51B, +3,1% YoY
• ▍Operating income +56,4% YoY
• ▍Net income +41,6% YoY
• ▍Free cash flow +1 067,8% YoY
• ▍Net margin 2.2%